{
    "clinical_study": {
        "@rank": "109283", 
        "acronym": "BACLOFEN III", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo every eight hours as inpatients for 72 hours or until discharge if less than 72 hours."
            }, 
            {
                "arm_group_label": "Baclofen", 
                "arm_group_type": "Active Comparator", 
                "description": "Baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is determine if the medication baclofen can prevent the symptoms\n      of Alcohol Withdrawal Syndrome (AWS) in hospitalized patients who may be at risk for AWS.\n      This medication is most often used for patients who have spasticity of their muscles due to\n      a neuromuscular disease.  In several European studies, and in an earlier study at Essentia\n      Health (NCT00597701), baclofen has been found to have a significant effect on the severity\n      of symptoms of AWS."
        }, 
        "brief_title": "Preventing Alcohol Withdrawal With Oral Baclofen", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Alcoholism", 
            "Alcohol Withdrawal"
        ], 
        "condition_browse": {
            "mesh_term": "Alcoholism"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults (>21) admitted to inpatients units of 1 of 3 Essentia Health hospitals\n\n          -  Patient placed on AWS watch protocol by admitting physicians.\n\n        Exclusion Criteria:\n\n          -  Unable to provide informed consent\n\n          -  Unable to take swallow oral medications (tube-fed patients are to be excluded)\n\n          -  Admitted for AWS or with CIWA-Ar score >8 at baseline\n\n          -  No alcohol intake for \u2265 48 hours or AUDIT score <12 at baseline\n\n          -  Baclofen use at baseline\n\n          -  Baclofen sensitivity\n\n          -  Hospital discharge anticipated in within 48 hours\n\n          -  Pregnant or breast feeding (urine pregnancy test required of women of child-bearing\n             potential)\n\n          -  Other active drug dependence (except tobacco)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "212", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01937364", 
            "org_study_id": "EIRH-13-1134"
        }, 
        "intervention": {
            "arm_group_label": "Baclofen", 
            "description": "Baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.", 
            "intervention_name": "Baclofen", 
            "intervention_type": "Drug", 
            "other_name": "lioresal"
        }, 
        "intervention_browse": {
            "mesh_term": "Baclofen"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 10, 2014", 
        "location": [
            {
                "contact": {
                    "email": "jeffrey.lyon@essentiahealth.org", 
                    "last_name": "Jeffrey E Lyon, MD", 
                    "phone": "218-786-2802"
                }, 
                "facility": {
                    "address": {
                        "city": "Duluth", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55805"
                    }, 
                    "name": "St. Mary's Medical Center"
                }, 
                "investigator": {
                    "last_name": "Jeffrey E Lyon, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "james.neumann@essentiahealth.org", 
                    "last_name": "James Neumann, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Fargo", 
                        "country": "United States", 
                        "state": "North Dakota", 
                        "zip": "58103"
                    }, 
                    "name": "Essentia Health Innovis Hospital"
                }, 
                "investigator": {
                    "last_name": "James Neumann, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Preventing Alcohol Withdrawal With Oral Baclofen: A Randomized, Placebo Controlled Trial", 
        "overall_contact": {
            "email": "jeffrey.lyon@essentiahealth.org", 
            "last_name": "Jeffrey E Lyon, MD", 
            "phone": "218-786-2802"
        }, 
        "overall_contact_backup": {
            "email": "steven.waring@essentiahealth.org", 
            "last_name": "Steven C Waring, DVM,PhD", 
            "phone": "218-786-1280"
        }, 
        "overall_official": {
            "affiliation": "Essentia Health", 
            "last_name": "Jeffrey E Lyon, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Alcohol withdrawal severity as measured on CIWA-AR (Clinical Institute for Withdrawal Assessment) scale", 
            "safety_issue": "Yes", 
            "time_frame": "72 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01937364"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Essentia Health", 
            "investigator_full_name": "Jeffrey E Lyon", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Total benzodiazepine dose required", 
            "safety_issue": "Yes", 
            "time_frame": "72 hours"
        }, 
        "source": "Essentia Health", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Essentia Health", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}